[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fRVHDPX2CC_1uDS1HOgE2hdQcCz6KrhWlOylBwNogVMs":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":70,"rows":77},"Mirati Therapeutics Inc.",[4],50,false,8,6,6279,18,1,[14,16,19,21,24,26,29,32],{"name":15,"count":8},"Advanced Cancer",{"name":17,"count":18},"Healthy Adults",5,{"name":20,"count":18},"Metastatic Cancer",{"name":22,"count":23},"Advanced Solid Tumor",4,{"name":25,"count":23},"Malignant Neoplastic Disease",{"name":27,"count":28},"Myelodysplastic Syndromes",3,{"name":30,"count":31},"Urothelial Carcinoma",2,{"name":33,"count":31},"Tumors",[35,40,44,49,54,58,62,66],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT04685135","Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation","2023-12-30","MRTX849",{"nctId":41,"briefTitle":42,"date":43,"intervention":39},"NCT04793958","Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)","2026-01-16",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT05609578","Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation","2026-06-01","Adagrasib oral dose of 400 mg twice daily",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT05853575","Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)","2026-07-30","Adagrasib",{"nctId":55,"briefTitle":56,"date":57,"intervention":39},"NCT03785249","Phase 1\u002F2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1","2026-12-31",{"nctId":59,"briefTitle":60,"date":61,"intervention":53},"NCT07415031","A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies","2028-02-16",{"nctId":63,"briefTitle":64,"date":65,"intervention":53},"NCT06875310","A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)","2029-09-07",{"nctId":67,"briefTitle":68,"date":69,"intervention":53},"NCT04613596","Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7","2032-06-09",[71,72,73,74,75,76],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[78,179,244,328,354,387,409,427,445,463,481,499,517,535,553,571,589,607,625,732,774,796,814,927,979,1014,1036,1054,1072,1101,1119,1137,1155,1173,1191,1216,1234,1252,1270,1288,1306,1337,1361,1379,1397,1415,1433,1460,1478,1496,1514,1532,1550,1574,1592,1618,1636,1662,1680],{"intervention":79,"totalTrials":80,"cells":81},"Pembrolizumab",7,{"EARLY_PHASE1":82,"PHASE1":85,"PHASE2":87,"PHASE3":141,"PHASE4":175,"NA":177},{"trials":83,"activeCount":84},[],0,{"trials":86,"activeCount":84},[],{"trials":88,"activeCount":28,"soonestReadout":47},[89,107,116,130],{"nctId":90,"briefTitle":91,"status":92,"phases":93,"primaryCompletion":94,"completion":95,"start":96,"enrollment":97,"conditions":98,"interventions":103},"NCT03606174","A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma","TERMINATED",[73],"2022-08-03","2022-08-22","2018-09-11",260,[30,99,100,101,102],"Urothelial Carcinoma Bladder","Urothelial Carcinoma Ureter","Urothelial Carcinoma of the Renal Pelvis and Ureter","Urothelial Carcinoma Urethra",[104,105,79,106],"Sitravatinib","Nivolumab","Enfortumab vedotin",{"nctId":55,"briefTitle":56,"status":108,"phases":109,"primaryCompletion":57,"completion":57,"start":110,"enrollment":111,"conditions":112,"interventions":113},"ACTIVE_NOT_RECRUITING",[72,73],"2019-01-15",731,[15,20,25],[39,79,114,115],"Cetuximab","Afatinib",{"nctId":59,"briefTitle":60,"status":117,"phases":118,"primaryCompletion":61,"completion":61,"start":119,"enrollment":120,"conditions":121,"interventions":123},"RECRUITING",[73],"2026-05-06",170,[122],"Solid Tumors",[53,79,114,124,125,126,127,128,129],"Pemetrexed","Docetaxel","Irinotecan","Leucovorin","Oxaliplatin","Fluorouracil",{"nctId":45,"briefTitle":46,"status":117,"phases":131,"primaryCompletion":47,"completion":132,"start":133,"enrollment":134,"conditions":135,"interventions":138},[73],"2026-12-01","2022-11-22",90,[136,137],"Advanced NSCLC","Metastatic Lung Cancer",[48,79,139,140],"Chemotherapy: Pemetrexed","Cisplatin\u002FCarboplatin",{"trials":142,"activeCount":31,"soonestReadout":65},[143,151,161],{"nctId":67,"briefTitle":68,"status":117,"phases":144,"primaryCompletion":69,"completion":69,"start":145,"enrollment":146,"conditions":147,"interventions":150},[73,74],"2020-12-02",626,[148,149],"Advanced Non-Small Cell Lung Cancer","Metastatic Non-Small Cell Lung Cancer",[53,53,53,53,79],{"nctId":63,"briefTitle":64,"status":117,"phases":152,"primaryCompletion":65,"completion":153,"start":154,"enrollment":155,"conditions":156,"interventions":158},[74],"2032-04-30","2025-04-24",630,[157],"Carcinoma, Non-Small-Cell Lung",[53,79,159,124,160],"Carboplatin","Cisplatin",{"nctId":162,"briefTitle":163,"status":164,"phases":165,"primaryCompletion":166,"completion":167,"start":168,"enrollment":169,"conditions":170,"interventions":172},"NCT04887870","Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study","COMPLETED",[73,74],"2025-04-21","2025-09-25","2021-06-29",52,[171],"Advanced or Metastatic Solid Malignancies",[104,105,79,173,174],"Enfortumab Vedotin-Ejfv","Ipilimumab",{"trials":176,"activeCount":84},[],{"trials":178,"activeCount":84},[],{"intervention":53,"totalTrials":80,"cells":180},{"EARLY_PHASE1":181,"PHASE1":183,"PHASE2":217,"PHASE3":230,"PHASE4":240,"NA":242},{"trials":182,"activeCount":84},[],{"trials":184,"activeCount":84},[185,195,206],{"nctId":186,"briefTitle":187,"status":164,"phases":188,"primaryCompletion":189,"completion":189,"start":190,"enrollment":191,"conditions":192,"interventions":194},"NCT06801418","Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets",[72],"2025-06-19","2025-02-04",160,[193],"Healthy Volunteers",[53],{"nctId":196,"briefTitle":197,"status":164,"phases":198,"primaryCompletion":199,"completion":200,"start":201,"enrollment":202,"conditions":203,"interventions":204},"NCT05924152","A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib",[72],"2023-08-09","2023-08-17","2023-06-29",16,[17],[53,205],"Eltrombopag + adagrasib",{"nctId":207,"briefTitle":208,"status":92,"phases":209,"primaryCompletion":210,"completion":210,"start":211,"enrollment":9,"conditions":212,"interventions":215},"NCT05840510","Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)",[72],"2024-12-27","2023-08-07",[213,214,15,20,25],"Solid Tumor, Adult","NSCLC",[53,216],"nab-Sirolimus",{"trials":218,"activeCount":31,"soonestReadout":52},[219,223],{"nctId":59,"briefTitle":60,"status":117,"phases":220,"primaryCompletion":61,"completion":61,"start":119,"enrollment":120,"conditions":221,"interventions":222},[73],[122],[53,79,114,124,125,126,127,128,129],{"nctId":50,"briefTitle":51,"status":108,"phases":224,"primaryCompletion":52,"completion":52,"start":225,"enrollment":226,"conditions":227,"interventions":229},[73],"2024-02-16",200,[15,20,228],"Malignant Neoplasm of Lung",[53],{"trials":231,"activeCount":31,"soonestReadout":65},[232,236],{"nctId":67,"briefTitle":68,"status":117,"phases":233,"primaryCompletion":69,"completion":69,"start":145,"enrollment":146,"conditions":234,"interventions":235},[73,74],[148,149],[53,53,53,53,79],{"nctId":63,"briefTitle":64,"status":117,"phases":237,"primaryCompletion":65,"completion":153,"start":154,"enrollment":155,"conditions":238,"interventions":239},[74],[157],[53,79,159,124,160],{"trials":241,"activeCount":84},[],{"trials":243,"activeCount":84},[],{"intervention":39,"totalTrials":80,"cells":245},{"EARLY_PHASE1":246,"PHASE1":248,"PHASE2":296,"PHASE3":302,"PHASE4":324,"NA":326},{"trials":247,"activeCount":84},[],{"trials":249,"activeCount":84},[250,261,272,283],{"nctId":251,"briefTitle":252,"status":164,"phases":253,"primaryCompletion":254,"completion":255,"start":256,"enrollment":257,"conditions":258,"interventions":259},"NCT04330664","Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)",[72],"2022-07-29","2025-02-24","2020-04-07",86,[15,20,25],[39,260],"TNO155",{"nctId":262,"briefTitle":263,"status":92,"phases":264,"primaryCompletion":265,"completion":266,"start":267,"enrollment":80,"conditions":268,"interventions":270},"NCT04975256","Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)",[72],"2022-11-02","2022-11-15","2021-07-28",[15,20,269,228,25],"Malignant Neoplasm of Colon",[39,271],"BI 1701963",{"nctId":273,"briefTitle":274,"status":164,"phases":275,"primaryCompletion":276,"completion":277,"start":278,"enrollment":279,"conditions":280,"interventions":281},"NCT05178888","Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)",[72],"2023-06-15","2024-12-30","2022-01-20",11,[22],[39,282],"Palbociclib",{"nctId":284,"briefTitle":285,"status":92,"phases":286,"primaryCompletion":287,"completion":287,"start":288,"enrollment":289,"conditions":290,"interventions":294},"NCT05578092","A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway",[72],"2026-02-03","2022-12-02",64,[291,22,292,293],"Solid Tumor","Non Small Cell Lung Cancer","Colo-rectal Cancer",[295,39],"MRTX0902",{"trials":297,"activeCount":12,"soonestReadout":57},[298],{"nctId":55,"briefTitle":56,"status":108,"phases":299,"primaryCompletion":57,"completion":57,"start":110,"enrollment":111,"conditions":300,"interventions":301},[72,73],[15,20,25],[39,79,114,115],{"trials":303,"activeCount":31,"soonestReadout":38},[304,313],{"nctId":36,"briefTitle":37,"status":108,"phases":305,"primaryCompletion":38,"completion":306,"start":307,"enrollment":308,"conditions":309,"interventions":312},[74],"2026-07-02","2021-02-23",453,[310,311],"Metastatic Non Small Cell Lung Cancer","Advanced Non Small Cell Lung Cancer",[39,125],{"nctId":41,"briefTitle":42,"status":108,"phases":314,"primaryCompletion":43,"completion":315,"start":316,"enrollment":317,"conditions":318,"interventions":321},[74],"2026-07-31","2021-07-19",461,[319,320],"Advanced Colorectal Cancer","Metastatic Colorectal Cancer",[39,114,322,323],"mFOLFOX6 Regimen","FOLFIRI Regimen",{"trials":325,"activeCount":84},[],{"trials":327,"activeCount":84},[],{"intervention":114,"totalTrials":28,"cells":329},{"EARLY_PHASE1":330,"PHASE1":332,"PHASE2":334,"PHASE3":344,"PHASE4":350,"NA":352},{"trials":331,"activeCount":84},[],{"trials":333,"activeCount":84},[],{"trials":335,"activeCount":31,"soonestReadout":57},[336,340],{"nctId":55,"briefTitle":56,"status":108,"phases":337,"primaryCompletion":57,"completion":57,"start":110,"enrollment":111,"conditions":338,"interventions":339},[72,73],[15,20,25],[39,79,114,115],{"nctId":59,"briefTitle":60,"status":117,"phases":341,"primaryCompletion":61,"completion":61,"start":119,"enrollment":120,"conditions":342,"interventions":343},[73],[122],[53,79,114,124,125,126,127,128,129],{"trials":345,"activeCount":12,"soonestReadout":43},[346],{"nctId":41,"briefTitle":42,"status":108,"phases":347,"primaryCompletion":43,"completion":315,"start":316,"enrollment":317,"conditions":348,"interventions":349},[74],[319,320],[39,114,322,323],{"trials":351,"activeCount":84},[],{"trials":353,"activeCount":84},[],{"intervention":125,"totalTrials":28,"cells":355},{"EARLY_PHASE1":356,"PHASE1":358,"PHASE2":360,"PHASE3":366,"PHASE4":383,"NA":385},{"trials":357,"activeCount":84},[],{"trials":359,"activeCount":84},[],{"trials":361,"activeCount":12,"soonestReadout":61},[362],{"nctId":59,"briefTitle":60,"status":117,"phases":363,"primaryCompletion":61,"completion":61,"start":119,"enrollment":120,"conditions":364,"interventions":365},[73],[122],[53,79,114,124,125,126,127,128,129],{"trials":367,"activeCount":12,"soonestReadout":38},[368,372],{"nctId":36,"briefTitle":37,"status":108,"phases":369,"primaryCompletion":38,"completion":306,"start":307,"enrollment":308,"conditions":370,"interventions":371},[74],[310,311],[39,125],{"nctId":373,"briefTitle":374,"status":164,"phases":375,"primaryCompletion":376,"completion":377,"start":378,"enrollment":379,"conditions":380,"interventions":382},"NCT03906071","Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer",[74],"2023-03-20","2025-09-30","2019-07-15",577,[381],"Metastatic Non-Squamous Non-Small Cell Lung Cancer",[105,104,125],{"trials":384,"activeCount":84},[],{"trials":386,"activeCount":84},[],{"intervention":124,"totalTrials":31,"cells":388},{"EARLY_PHASE1":389,"PHASE1":391,"PHASE2":393,"PHASE3":399,"PHASE4":405,"NA":407},{"trials":390,"activeCount":84},[],{"trials":392,"activeCount":84},[],{"trials":394,"activeCount":12,"soonestReadout":61},[395],{"nctId":59,"briefTitle":60,"status":117,"phases":396,"primaryCompletion":61,"completion":61,"start":119,"enrollment":120,"conditions":397,"interventions":398},[73],[122],[53,79,114,124,125,126,127,128,129],{"trials":400,"activeCount":12,"soonestReadout":65},[401],{"nctId":63,"briefTitle":64,"status":117,"phases":402,"primaryCompletion":65,"completion":153,"start":154,"enrollment":155,"conditions":403,"interventions":404},[74],[157],[53,79,159,124,160],{"trials":406,"activeCount":84},[],{"trials":408,"activeCount":84},[],{"intervention":322,"totalTrials":12,"cells":410},{"EARLY_PHASE1":411,"PHASE1":413,"PHASE2":415,"PHASE3":417,"PHASE4":423,"NA":425},{"trials":412,"activeCount":84},[],{"trials":414,"activeCount":84},[],{"trials":416,"activeCount":84},[],{"trials":418,"activeCount":12,"soonestReadout":43},[419],{"nctId":41,"briefTitle":42,"status":108,"phases":420,"primaryCompletion":43,"completion":315,"start":316,"enrollment":317,"conditions":421,"interventions":422},[74],[319,320],[39,114,322,323],{"trials":424,"activeCount":84},[],{"trials":426,"activeCount":84},[],{"intervention":323,"totalTrials":12,"cells":428},{"EARLY_PHASE1":429,"PHASE1":431,"PHASE2":433,"PHASE3":435,"PHASE4":441,"NA":443},{"trials":430,"activeCount":84},[],{"trials":432,"activeCount":84},[],{"trials":434,"activeCount":84},[],{"trials":436,"activeCount":12,"soonestReadout":43},[437],{"nctId":41,"briefTitle":42,"status":108,"phases":438,"primaryCompletion":43,"completion":315,"start":316,"enrollment":317,"conditions":439,"interventions":440},[74],[319,320],[39,114,322,323],{"trials":442,"activeCount":84},[],{"trials":444,"activeCount":84},[],{"intervention":159,"totalTrials":12,"cells":446},{"EARLY_PHASE1":447,"PHASE1":449,"PHASE2":451,"PHASE3":453,"PHASE4":459,"NA":461},{"trials":448,"activeCount":84},[],{"trials":450,"activeCount":84},[],{"trials":452,"activeCount":84},[],{"trials":454,"activeCount":12,"soonestReadout":65},[455],{"nctId":63,"briefTitle":64,"status":117,"phases":456,"primaryCompletion":65,"completion":153,"start":154,"enrollment":155,"conditions":457,"interventions":458},[74],[157],[53,79,159,124,160],{"trials":460,"activeCount":84},[],{"trials":462,"activeCount":84},[],{"intervention":160,"totalTrials":12,"cells":464},{"EARLY_PHASE1":465,"PHASE1":467,"PHASE2":469,"PHASE3":471,"PHASE4":477,"NA":479},{"trials":466,"activeCount":84},[],{"trials":468,"activeCount":84},[],{"trials":470,"activeCount":84},[],{"trials":472,"activeCount":12,"soonestReadout":65},[473],{"nctId":63,"briefTitle":64,"status":117,"phases":474,"primaryCompletion":65,"completion":153,"start":154,"enrollment":155,"conditions":475,"interventions":476},[74],[157],[53,79,159,124,160],{"trials":478,"activeCount":84},[],{"trials":480,"activeCount":84},[],{"intervention":115,"totalTrials":12,"cells":482},{"EARLY_PHASE1":483,"PHASE1":485,"PHASE2":487,"PHASE3":493,"PHASE4":495,"NA":497},{"trials":484,"activeCount":84},[],{"trials":486,"activeCount":84},[],{"trials":488,"activeCount":12,"soonestReadout":57},[489],{"nctId":55,"briefTitle":56,"status":108,"phases":490,"primaryCompletion":57,"completion":57,"start":110,"enrollment":111,"conditions":491,"interventions":492},[72,73],[15,20,25],[39,79,114,115],{"trials":494,"activeCount":84},[],{"trials":496,"activeCount":84},[],{"trials":498,"activeCount":84},[],{"intervention":126,"totalTrials":12,"cells":500},{"EARLY_PHASE1":501,"PHASE1":503,"PHASE2":505,"PHASE3":511,"PHASE4":513,"NA":515},{"trials":502,"activeCount":84},[],{"trials":504,"activeCount":84},[],{"trials":506,"activeCount":12,"soonestReadout":61},[507],{"nctId":59,"briefTitle":60,"status":117,"phases":508,"primaryCompletion":61,"completion":61,"start":119,"enrollment":120,"conditions":509,"interventions":510},[73],[122],[53,79,114,124,125,126,127,128,129],{"trials":512,"activeCount":84},[],{"trials":514,"activeCount":84},[],{"trials":516,"activeCount":84},[],{"intervention":127,"totalTrials":12,"cells":518},{"EARLY_PHASE1":519,"PHASE1":521,"PHASE2":523,"PHASE3":529,"PHASE4":531,"NA":533},{"trials":520,"activeCount":84},[],{"trials":522,"activeCount":84},[],{"trials":524,"activeCount":12,"soonestReadout":61},[525],{"nctId":59,"briefTitle":60,"status":117,"phases":526,"primaryCompletion":61,"completion":61,"start":119,"enrollment":120,"conditions":527,"interventions":528},[73],[122],[53,79,114,124,125,126,127,128,129],{"trials":530,"activeCount":84},[],{"trials":532,"activeCount":84},[],{"trials":534,"activeCount":84},[],{"intervention":128,"totalTrials":12,"cells":536},{"EARLY_PHASE1":537,"PHASE1":539,"PHASE2":541,"PHASE3":547,"PHASE4":549,"NA":551},{"trials":538,"activeCount":84},[],{"trials":540,"activeCount":84},[],{"trials":542,"activeCount":12,"soonestReadout":61},[543],{"nctId":59,"briefTitle":60,"status":117,"phases":544,"primaryCompletion":61,"completion":61,"start":119,"enrollment":120,"conditions":545,"interventions":546},[73],[122],[53,79,114,124,125,126,127,128,129],{"trials":548,"activeCount":84},[],{"trials":550,"activeCount":84},[],{"trials":552,"activeCount":84},[],{"intervention":129,"totalTrials":12,"cells":554},{"EARLY_PHASE1":555,"PHASE1":557,"PHASE2":559,"PHASE3":565,"PHASE4":567,"NA":569},{"trials":556,"activeCount":84},[],{"trials":558,"activeCount":84},[],{"trials":560,"activeCount":12,"soonestReadout":61},[561],{"nctId":59,"briefTitle":60,"status":117,"phases":562,"primaryCompletion":61,"completion":61,"start":119,"enrollment":120,"conditions":563,"interventions":564},[73],[122],[53,79,114,124,125,126,127,128,129],{"trials":566,"activeCount":84},[],{"trials":568,"activeCount":84},[],{"trials":570,"activeCount":84},[],{"intervention":48,"totalTrials":12,"cells":572},{"EARLY_PHASE1":573,"PHASE1":575,"PHASE2":577,"PHASE3":583,"PHASE4":585,"NA":587},{"trials":574,"activeCount":84},[],{"trials":576,"activeCount":84},[],{"trials":578,"activeCount":12,"soonestReadout":47},[579],{"nctId":45,"briefTitle":46,"status":117,"phases":580,"primaryCompletion":47,"completion":132,"start":133,"enrollment":134,"conditions":581,"interventions":582},[73],[136,137],[48,79,139,140],{"trials":584,"activeCount":84},[],{"trials":586,"activeCount":84},[],{"trials":588,"activeCount":84},[],{"intervention":139,"totalTrials":12,"cells":590},{"EARLY_PHASE1":591,"PHASE1":593,"PHASE2":595,"PHASE3":601,"PHASE4":603,"NA":605},{"trials":592,"activeCount":84},[],{"trials":594,"activeCount":84},[],{"trials":596,"activeCount":12,"soonestReadout":47},[597],{"nctId":45,"briefTitle":46,"status":117,"phases":598,"primaryCompletion":47,"completion":132,"start":133,"enrollment":134,"conditions":599,"interventions":600},[73],[136,137],[48,79,139,140],{"trials":602,"activeCount":84},[],{"trials":604,"activeCount":84},[],{"trials":606,"activeCount":84},[],{"intervention":140,"totalTrials":12,"cells":608},{"EARLY_PHASE1":609,"PHASE1":611,"PHASE2":613,"PHASE3":619,"PHASE4":621,"NA":623},{"trials":610,"activeCount":84},[],{"trials":612,"activeCount":84},[],{"trials":614,"activeCount":12,"soonestReadout":47},[615],{"nctId":45,"briefTitle":46,"status":117,"phases":616,"primaryCompletion":47,"completion":132,"start":133,"enrollment":134,"conditions":617,"interventions":618},[73],[136,137],[48,79,139,140],{"trials":620,"activeCount":84},[],{"trials":622,"activeCount":84},[],{"trials":624,"activeCount":84},[],{"intervention":104,"totalTrials":626,"cells":627},10,{"EARLY_PHASE1":628,"PHASE1":630,"PHASE2":690,"PHASE3":718,"PHASE4":728,"NA":730},{"trials":629,"activeCount":84},[],{"trials":631,"activeCount":84},[632,643,657,667,678],{"nctId":633,"briefTitle":634,"status":164,"phases":635,"primaryCompletion":636,"completion":637,"start":638,"enrollment":639,"conditions":640,"interventions":641},"NCT04800614","A Study to Explore the Effect of Food Before a Single Dose of Sitravatinib",[72],"2021-07-06","2022-03-28","2021-03-15",36,[17],[642],"sitravatinib",{"nctId":644,"briefTitle":645,"status":164,"phases":646,"primaryCompletion":647,"completion":647,"start":648,"enrollment":649,"conditions":650,"interventions":651},"NCT04887194","PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates",[72],"2022-12-22","2021-04-08",40,[22],[104,652,653,654,655,656,105],"Warfarin","Dextromethorphan","Midazolam","Digoxin","Rosuvastatin",{"nctId":658,"briefTitle":659,"status":164,"phases":660,"primaryCompletion":661,"completion":661,"start":662,"enrollment":663,"conditions":664,"interventions":666},"NCT04518046","Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies",[72],"2023-06-30","2020-08-11",22,[665],"Clear-Cell Renal Cell Carcinoma",[104,105,174],{"nctId":668,"briefTitle":669,"status":164,"phases":670,"primaryCompletion":671,"completion":672,"start":673,"enrollment":674,"conditions":675,"interventions":677},"NCT04772612","A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib",[72],"2022-07-13","2023-04-13","2021-03-12",30,[676],"Hepatic Impairment",[642],{"nctId":679,"briefTitle":680,"status":164,"phases":681,"primaryCompletion":682,"completion":683,"start":684,"enrollment":685,"conditions":686,"interventions":687},"NCT04935112","A Study to Explore the Effect of Acid-reducing Agents",[72],"2021-08-12","2022-07-12","2021-07-07",15,[17],[104,688,689],"Pantoprazole","Famotidine",{"trials":691,"activeCount":84},[692,696,707],{"nctId":90,"briefTitle":91,"status":92,"phases":693,"primaryCompletion":94,"completion":95,"start":96,"enrollment":97,"conditions":694,"interventions":695},[73],[30,99,100,101,102],[104,105,79,106],{"nctId":697,"briefTitle":698,"status":92,"phases":699,"primaryCompletion":700,"completion":700,"start":701,"enrollment":702,"conditions":703,"interventions":704},"NCT02954991","Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer",[73],"2021-11-04","2016-11-07",161,[157],[705,104,706,105],"Glesatinib","Mocetinostat",{"nctId":708,"briefTitle":709,"status":164,"phases":710,"primaryCompletion":711,"completion":712,"start":713,"enrollment":714,"conditions":715,"interventions":717},"NCT03680521","Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma",[73],"2020-04-27","2023-05-18","2018-10-10",25,[716],"Clear Cell Renal Cell Carcinoma",[104,105],{"trials":719,"activeCount":84},[720,724],{"nctId":373,"briefTitle":374,"status":164,"phases":721,"primaryCompletion":376,"completion":377,"start":378,"enrollment":379,"conditions":722,"interventions":723},[74],[381],[105,104,125],{"nctId":162,"briefTitle":163,"status":164,"phases":725,"primaryCompletion":166,"completion":167,"start":168,"enrollment":169,"conditions":726,"interventions":727},[73,74],[171],[104,105,79,173,174],{"trials":729,"activeCount":84},[],{"trials":731,"activeCount":84},[],{"intervention":105,"totalTrials":80,"cells":733},{"EARLY_PHASE1":734,"PHASE1":736,"PHASE2":746,"PHASE3":760,"PHASE4":770,"NA":772},{"trials":735,"activeCount":84},[],{"trials":737,"activeCount":84},[738,742],{"nctId":644,"briefTitle":645,"status":164,"phases":739,"primaryCompletion":647,"completion":647,"start":648,"enrollment":649,"conditions":740,"interventions":741},[72],[22],[104,652,653,654,655,656,105],{"nctId":658,"briefTitle":659,"status":164,"phases":743,"primaryCompletion":661,"completion":661,"start":662,"enrollment":663,"conditions":744,"interventions":745},[72],[665],[104,105,174],{"trials":747,"activeCount":84},[748,752,756],{"nctId":90,"briefTitle":91,"status":92,"phases":749,"primaryCompletion":94,"completion":95,"start":96,"enrollment":97,"conditions":750,"interventions":751},[73],[30,99,100,101,102],[104,105,79,106],{"nctId":697,"briefTitle":698,"status":92,"phases":753,"primaryCompletion":700,"completion":700,"start":701,"enrollment":702,"conditions":754,"interventions":755},[73],[157],[705,104,706,105],{"nctId":708,"briefTitle":709,"status":164,"phases":757,"primaryCompletion":711,"completion":712,"start":713,"enrollment":714,"conditions":758,"interventions":759},[73],[716],[104,105],{"trials":761,"activeCount":84},[762,766],{"nctId":373,"briefTitle":374,"status":164,"phases":763,"primaryCompletion":376,"completion":377,"start":378,"enrollment":379,"conditions":764,"interventions":765},[74],[381],[105,104,125],{"nctId":162,"briefTitle":163,"status":164,"phases":767,"primaryCompletion":166,"completion":167,"start":168,"enrollment":169,"conditions":768,"interventions":769},[73,74],[171],[104,105,79,173,174],{"trials":771,"activeCount":84},[],{"trials":773,"activeCount":84},[],{"intervention":174,"totalTrials":31,"cells":775},{"EARLY_PHASE1":776,"PHASE1":778,"PHASE2":784,"PHASE3":786,"PHASE4":792,"NA":794},{"trials":777,"activeCount":84},[],{"trials":779,"activeCount":84},[780],{"nctId":658,"briefTitle":659,"status":164,"phases":781,"primaryCompletion":661,"completion":661,"start":662,"enrollment":663,"conditions":782,"interventions":783},[72],[665],[104,105,174],{"trials":785,"activeCount":84},[],{"trials":787,"activeCount":84},[788],{"nctId":162,"briefTitle":163,"status":164,"phases":789,"primaryCompletion":166,"completion":167,"start":168,"enrollment":169,"conditions":790,"interventions":791},[73,74],[171],[104,105,79,173,174],{"trials":793,"activeCount":84},[],{"trials":795,"activeCount":84},[],{"intervention":173,"totalTrials":12,"cells":797},{"EARLY_PHASE1":798,"PHASE1":800,"PHASE2":802,"PHASE3":804,"PHASE4":810,"NA":812},{"trials":799,"activeCount":84},[],{"trials":801,"activeCount":84},[],{"trials":803,"activeCount":84},[],{"trials":805,"activeCount":84},[806],{"nctId":162,"briefTitle":163,"status":164,"phases":807,"primaryCompletion":166,"completion":167,"start":168,"enrollment":169,"conditions":808,"interventions":809},[73,74],[171],[104,105,79,173,174],{"trials":811,"activeCount":84},[],{"trials":813,"activeCount":84},[],{"intervention":815,"totalTrials":626,"cells":816},"MGCD0103",{"EARLY_PHASE1":817,"PHASE1":819,"PHASE2":851,"PHASE3":921,"PHASE4":923,"NA":925},{"trials":818,"activeCount":84},[],{"trials":820,"activeCount":84},[821,832,842],{"nctId":822,"briefTitle":823,"status":164,"phases":824,"primaryCompletion":825,"completion":826,"start":827,"enrollment":828,"conditions":829,"interventions":831},"NCT00323934","Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma",[72],"2007-10","2008-10","2004-04",42,[33,830],"Non Hodgkin's Lymphoma",[815],{"nctId":833,"briefTitle":834,"status":164,"phases":835,"primaryCompletion":836,"completion":837,"start":838,"enrollment":714,"conditions":839,"interventions":841},"NCT00324194","A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes",[72],"2008-03","2008-08","2005-02",[840,27],"Leukemia",[815],{"nctId":843,"briefTitle":844,"status":164,"phases":845,"primaryCompletion":846,"completion":847,"start":838,"enrollment":848,"conditions":849,"interventions":850},"NCT00324129","A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes",[72],"2006-07","2008-12",29,[840,27],[815],{"trials":852,"activeCount":84},[853,863,873,883,894,902,912],{"nctId":854,"briefTitle":855,"status":164,"phases":856,"primaryCompletion":857,"completion":857,"start":858,"enrollment":859,"conditions":860,"interventions":862},"NCT00431873","A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia",[73],"2008-11","2007-01",21,[861],"Lymphocytic Leukemia, Chronic",[815],{"nctId":864,"briefTitle":865,"status":92,"phases":866,"primaryCompletion":867,"completion":867,"start":868,"enrollment":869,"conditions":870,"interventions":872},"NCT00374296","MGCD0103 in Elderly Patients With Previously Untreated AML\u002FHigh Risk MDS or Adults With Relapsed\u002FRefractory Disease",[73],"2008-09","2006-09",35,[871,27],"Myelogenous Leukemia, Acute",[815],{"nctId":874,"briefTitle":875,"status":164,"phases":876,"primaryCompletion":857,"completion":857,"start":877,"enrollment":878,"conditions":879,"interventions":882},"NCT00324220","A Phase I\u002FII Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia",[72,73],"2006-01",66,[880,881],"Myelodysplastic Syndrome","Acute Myelogenous Leukemia",[815],{"nctId":884,"briefTitle":885,"status":92,"phases":886,"primaryCompletion":887,"completion":887,"start":888,"enrollment":9,"conditions":889,"interventions":892},"NCT00666497","Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)",[73],"2009-04","2008-06",[890,891],"Acute Myeloid Leukemia (AML)","Myelodysplastic Syndrome (MDS)",[893,815,815],"Azacitidine",{"nctId":895,"briefTitle":896,"status":164,"phases":897,"primaryCompletion":847,"completion":847,"start":868,"enrollment":898,"conditions":899,"interventions":900},"NCT00372437","A Phase I\u002FII Study of MGCD0103 (MG-0103) in Combination With Gemcitabine",[72,73],47,[33],[815,901],"Gemcitabine",{"nctId":903,"briefTitle":904,"status":164,"phases":905,"primaryCompletion":906,"completion":906,"start":907,"enrollment":908,"conditions":909,"interventions":911},"NCT00359086","Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma",[73],"2012-01","2006-08",74,[910],"Lymphoma",[815],{"nctId":913,"briefTitle":914,"status":92,"phases":915,"primaryCompletion":916,"completion":916,"start":907,"enrollment":917,"conditions":918,"interventions":920},"NCT00358982","Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma",[73],"2009-01",51,[919],"Hodgkin's Lymphoma",[815],{"trials":922,"activeCount":84},[],{"trials":924,"activeCount":84},[],{"trials":926,"activeCount":84},[],{"intervention":928,"totalTrials":23,"cells":929},"MGCD265",{"EARLY_PHASE1":930,"PHASE1":932,"PHASE2":961,"PHASE3":973,"PHASE4":975,"NA":977},{"trials":931,"activeCount":84},[],{"trials":933,"activeCount":84},[934,943,952],{"nctId":935,"briefTitle":936,"status":164,"phases":937,"primaryCompletion":938,"completion":938,"start":939,"enrollment":898,"conditions":940,"interventions":942},"NCT00679133","Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies",[72],"2011-03","2008-04",[941],"Advanced Malignancies",[928],{"nctId":944,"briefTitle":945,"status":164,"phases":946,"primaryCompletion":947,"completion":948,"start":888,"enrollment":949,"conditions":950,"interventions":951},"NCT00697632","Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies",[72],"2018-09","2019-01",180,[15],[928],{"nctId":953,"briefTitle":954,"status":164,"phases":955,"primaryCompletion":956,"completion":956,"start":957,"enrollment":958,"conditions":959,"interventions":960},"NCT01930006","Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State",[72],"2013-12","2013-08",14,[941],[928],{"trials":962,"activeCount":84},[963],{"nctId":964,"briefTitle":965,"status":164,"phases":966,"primaryCompletion":967,"completion":948,"start":968,"enrollment":969,"conditions":970,"interventions":972},"NCT02544633","Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET",[73],"2018-04-30","2015-10",68,[971],"Non-Small Cell Lung Cancer",[928],{"trials":974,"activeCount":84},[],{"trials":976,"activeCount":84},[],{"trials":978,"activeCount":84},[],{"intervention":706,"totalTrials":28,"cells":980},{"EARLY_PHASE1":981,"PHASE1":983,"PHASE2":985,"PHASE3":1008,"PHASE4":1010,"NA":1012},{"trials":982,"activeCount":84},[],{"trials":984,"activeCount":84},[],{"trials":986,"activeCount":84},[987,991,1001],{"nctId":697,"briefTitle":698,"status":92,"phases":988,"primaryCompletion":700,"completion":700,"start":701,"enrollment":702,"conditions":989,"interventions":990},[73],[157],[705,104,706,105],{"nctId":992,"briefTitle":993,"status":164,"phases":994,"primaryCompletion":995,"completion":996,"start":997,"enrollment":998,"conditions":999,"interventions":1000},"NCT02236195","Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes",[73],"2016-04","2016-07","2014-10",17,[30],[706],{"nctId":1002,"briefTitle":1003,"status":164,"phases":1004,"primaryCompletion":1005,"completion":1005,"start":956,"enrollment":11,"conditions":1006,"interventions":1007},"NCT02018926","Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS",[72,73],"2015-09",[880],[706,893],{"trials":1009,"activeCount":84},[],{"trials":1011,"activeCount":84},[],{"trials":1013,"activeCount":84},[],{"intervention":893,"totalTrials":31,"cells":1015},{"EARLY_PHASE1":1016,"PHASE1":1018,"PHASE2":1020,"PHASE3":1030,"PHASE4":1032,"NA":1034},{"trials":1017,"activeCount":84},[],{"trials":1019,"activeCount":84},[],{"trials":1021,"activeCount":84},[1022,1026],{"nctId":884,"briefTitle":885,"status":92,"phases":1023,"primaryCompletion":887,"completion":887,"start":888,"enrollment":9,"conditions":1024,"interventions":1025},[73],[890,891],[893,815,815],{"nctId":1002,"briefTitle":1003,"status":164,"phases":1027,"primaryCompletion":1005,"completion":1005,"start":956,"enrollment":11,"conditions":1028,"interventions":1029},[72,73],[880],[706,893],{"trials":1031,"activeCount":84},[],{"trials":1033,"activeCount":84},[],{"trials":1035,"activeCount":84},[],{"intervention":106,"totalTrials":12,"cells":1037},{"EARLY_PHASE1":1038,"PHASE1":1040,"PHASE2":1042,"PHASE3":1048,"PHASE4":1050,"NA":1052},{"trials":1039,"activeCount":84},[],{"trials":1041,"activeCount":84},[],{"trials":1043,"activeCount":84},[1044],{"nctId":90,"briefTitle":91,"status":92,"phases":1045,"primaryCompletion":94,"completion":95,"start":96,"enrollment":97,"conditions":1046,"interventions":1047},[73],[30,99,100,101,102],[104,105,79,106],{"trials":1049,"activeCount":84},[],{"trials":1051,"activeCount":84},[],{"trials":1053,"activeCount":84},[],{"intervention":705,"totalTrials":12,"cells":1055},{"EARLY_PHASE1":1056,"PHASE1":1058,"PHASE2":1060,"PHASE3":1066,"PHASE4":1068,"NA":1070},{"trials":1057,"activeCount":84},[],{"trials":1059,"activeCount":84},[],{"trials":1061,"activeCount":84},[1062],{"nctId":697,"briefTitle":698,"status":92,"phases":1063,"primaryCompletion":700,"completion":700,"start":701,"enrollment":702,"conditions":1064,"interventions":1065},[73],[157],[705,104,706,105],{"trials":1067,"activeCount":84},[],{"trials":1069,"activeCount":84},[],{"trials":1071,"activeCount":84},[],{"intervention":1073,"totalTrials":12,"cells":1074},"Mocetinostat - 50 mg",{"EARLY_PHASE1":1075,"PHASE1":1077,"PHASE2":1079,"PHASE3":1095,"PHASE4":1097,"NA":1099},{"trials":1076,"activeCount":84},[],{"trials":1078,"activeCount":84},[],{"trials":1080,"activeCount":84},[1081],{"nctId":1082,"briefTitle":1083,"status":92,"phases":1084,"primaryCompletion":1085,"completion":1086,"start":1087,"enrollment":1088,"conditions":1089,"interventions":1090},"NCT02805660","Phase 1\u002F2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC",[72,73],"2019-12-14","2019-12-20","2016-06-01",83,[15],[1073,1091,1092,1093,1094],"Mocetinostat - 70 mg","Mocetinostat - 90 mg","Mocetinostat - Recommended Phase 2 Dose","Durvalumab - 1500 mg",{"trials":1096,"activeCount":84},[],{"trials":1098,"activeCount":84},[],{"trials":1100,"activeCount":84},[],{"intervention":1091,"totalTrials":12,"cells":1102},{"EARLY_PHASE1":1103,"PHASE1":1105,"PHASE2":1107,"PHASE3":1113,"PHASE4":1115,"NA":1117},{"trials":1104,"activeCount":84},[],{"trials":1106,"activeCount":84},[],{"trials":1108,"activeCount":84},[1109],{"nctId":1082,"briefTitle":1083,"status":92,"phases":1110,"primaryCompletion":1085,"completion":1086,"start":1087,"enrollment":1088,"conditions":1111,"interventions":1112},[72,73],[15],[1073,1091,1092,1093,1094],{"trials":1114,"activeCount":84},[],{"trials":1116,"activeCount":84},[],{"trials":1118,"activeCount":84},[],{"intervention":1092,"totalTrials":12,"cells":1120},{"EARLY_PHASE1":1121,"PHASE1":1123,"PHASE2":1125,"PHASE3":1131,"PHASE4":1133,"NA":1135},{"trials":1122,"activeCount":84},[],{"trials":1124,"activeCount":84},[],{"trials":1126,"activeCount":84},[1127],{"nctId":1082,"briefTitle":1083,"status":92,"phases":1128,"primaryCompletion":1085,"completion":1086,"start":1087,"enrollment":1088,"conditions":1129,"interventions":1130},[72,73],[15],[1073,1091,1092,1093,1094],{"trials":1132,"activeCount":84},[],{"trials":1134,"activeCount":84},[],{"trials":1136,"activeCount":84},[],{"intervention":1093,"totalTrials":12,"cells":1138},{"EARLY_PHASE1":1139,"PHASE1":1141,"PHASE2":1143,"PHASE3":1149,"PHASE4":1151,"NA":1153},{"trials":1140,"activeCount":84},[],{"trials":1142,"activeCount":84},[],{"trials":1144,"activeCount":84},[1145],{"nctId":1082,"briefTitle":1083,"status":92,"phases":1146,"primaryCompletion":1085,"completion":1086,"start":1087,"enrollment":1088,"conditions":1147,"interventions":1148},[72,73],[15],[1073,1091,1092,1093,1094],{"trials":1150,"activeCount":84},[],{"trials":1152,"activeCount":84},[],{"trials":1154,"activeCount":84},[],{"intervention":1094,"totalTrials":12,"cells":1156},{"EARLY_PHASE1":1157,"PHASE1":1159,"PHASE2":1161,"PHASE3":1167,"PHASE4":1169,"NA":1171},{"trials":1158,"activeCount":84},[],{"trials":1160,"activeCount":84},[],{"trials":1162,"activeCount":84},[1163],{"nctId":1082,"briefTitle":1083,"status":92,"phases":1164,"primaryCompletion":1085,"completion":1086,"start":1087,"enrollment":1088,"conditions":1165,"interventions":1166},[72,73],[15],[1073,1091,1092,1093,1094],{"trials":1168,"activeCount":84},[],{"trials":1170,"activeCount":84},[],{"trials":1172,"activeCount":84},[],{"intervention":901,"totalTrials":12,"cells":1174},{"EARLY_PHASE1":1175,"PHASE1":1177,"PHASE2":1179,"PHASE3":1185,"PHASE4":1187,"NA":1189},{"trials":1176,"activeCount":84},[],{"trials":1178,"activeCount":84},[],{"trials":1180,"activeCount":84},[1181],{"nctId":895,"briefTitle":896,"status":164,"phases":1182,"primaryCompletion":847,"completion":847,"start":868,"enrollment":898,"conditions":1183,"interventions":1184},[72,73],[33],[815,901],{"trials":1186,"activeCount":84},[],{"trials":1188,"activeCount":84},[],{"trials":1190,"activeCount":84},[],{"intervention":1192,"totalTrials":12,"cells":1193},"MGCD0103 and Azacitidine",{"EARLY_PHASE1":1194,"PHASE1":1196,"PHASE2":1198,"PHASE3":1210,"PHASE4":1212,"NA":1214},{"trials":1195,"activeCount":84},[],{"trials":1197,"activeCount":84},[],{"trials":1199,"activeCount":84},[1200],{"nctId":1201,"briefTitle":1202,"status":92,"phases":1203,"primaryCompletion":1204,"completion":1204,"start":825,"enrollment":1205,"conditions":1206,"interventions":1209},"NCT00543582","MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma",[73],"2009-03",23,[1207,1208],"Hodgkin Lymphoma","Non-Hodgkin Lymphoma (Follicular or Large Diffuse B-cell Lymphoma or Mantle Cell Lymphoma)",[1192],{"trials":1211,"activeCount":84},[],{"trials":1213,"activeCount":84},[],{"trials":1215,"activeCount":84},[],{"intervention":652,"totalTrials":12,"cells":1217},{"EARLY_PHASE1":1218,"PHASE1":1220,"PHASE2":1226,"PHASE3":1228,"PHASE4":1230,"NA":1232},{"trials":1219,"activeCount":84},[],{"trials":1221,"activeCount":84},[1222],{"nctId":644,"briefTitle":645,"status":164,"phases":1223,"primaryCompletion":647,"completion":647,"start":648,"enrollment":649,"conditions":1224,"interventions":1225},[72],[22],[104,652,653,654,655,656,105],{"trials":1227,"activeCount":84},[],{"trials":1229,"activeCount":84},[],{"trials":1231,"activeCount":84},[],{"trials":1233,"activeCount":84},[],{"intervention":653,"totalTrials":12,"cells":1235},{"EARLY_PHASE1":1236,"PHASE1":1238,"PHASE2":1244,"PHASE3":1246,"PHASE4":1248,"NA":1250},{"trials":1237,"activeCount":84},[],{"trials":1239,"activeCount":84},[1240],{"nctId":644,"briefTitle":645,"status":164,"phases":1241,"primaryCompletion":647,"completion":647,"start":648,"enrollment":649,"conditions":1242,"interventions":1243},[72],[22],[104,652,653,654,655,656,105],{"trials":1245,"activeCount":84},[],{"trials":1247,"activeCount":84},[],{"trials":1249,"activeCount":84},[],{"trials":1251,"activeCount":84},[],{"intervention":654,"totalTrials":12,"cells":1253},{"EARLY_PHASE1":1254,"PHASE1":1256,"PHASE2":1262,"PHASE3":1264,"PHASE4":1266,"NA":1268},{"trials":1255,"activeCount":84},[],{"trials":1257,"activeCount":84},[1258],{"nctId":644,"briefTitle":645,"status":164,"phases":1259,"primaryCompletion":647,"completion":647,"start":648,"enrollment":649,"conditions":1260,"interventions":1261},[72],[22],[104,652,653,654,655,656,105],{"trials":1263,"activeCount":84},[],{"trials":1265,"activeCount":84},[],{"trials":1267,"activeCount":84},[],{"trials":1269,"activeCount":84},[],{"intervention":655,"totalTrials":12,"cells":1271},{"EARLY_PHASE1":1272,"PHASE1":1274,"PHASE2":1280,"PHASE3":1282,"PHASE4":1284,"NA":1286},{"trials":1273,"activeCount":84},[],{"trials":1275,"activeCount":84},[1276],{"nctId":644,"briefTitle":645,"status":164,"phases":1277,"primaryCompletion":647,"completion":647,"start":648,"enrollment":649,"conditions":1278,"interventions":1279},[72],[22],[104,652,653,654,655,656,105],{"trials":1281,"activeCount":84},[],{"trials":1283,"activeCount":84},[],{"trials":1285,"activeCount":84},[],{"trials":1287,"activeCount":84},[],{"intervention":656,"totalTrials":12,"cells":1289},{"EARLY_PHASE1":1290,"PHASE1":1292,"PHASE2":1298,"PHASE3":1300,"PHASE4":1302,"NA":1304},{"trials":1291,"activeCount":84},[],{"trials":1293,"activeCount":84},[1294],{"nctId":644,"briefTitle":645,"status":164,"phases":1295,"primaryCompletion":647,"completion":647,"start":648,"enrollment":649,"conditions":1296,"interventions":1297},[72],[22],[104,652,653,654,655,656,105],{"trials":1299,"activeCount":84},[],{"trials":1301,"activeCount":84},[],{"trials":1303,"activeCount":84},[],{"trials":1305,"activeCount":84},[],{"intervention":1307,"totalTrials":12,"cells":1308},"MGCD0103 & Docetaxel",{"EARLY_PHASE1":1309,"PHASE1":1311,"PHASE2":1329,"PHASE3":1331,"PHASE4":1333,"NA":1335},{"trials":1310,"activeCount":84},[],{"trials":1312,"activeCount":84},[1313],{"nctId":1314,"briefTitle":1315,"status":92,"phases":1316,"primaryCompletion":1204,"completion":1204,"start":1317,"enrollment":1318,"conditions":1319,"interventions":1328},"NCT00511576","Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors",[72],"2007-08",54,[1320,1321,1322,1323,1324,1325,1326,1327],"Breast Cancer","Lung Cancer","Pulmonary Cancer","Non-Small-Cell Lung Carcinoma","Prostate Cancer","Prostatic Cancer","Gastric Cancer","Stomach Cancer",[1307],{"trials":1330,"activeCount":84},[],{"trials":1332,"activeCount":84},[],{"trials":1334,"activeCount":84},[],{"trials":1336,"activeCount":84},[],{"intervention":1338,"totalTrials":12,"cells":1339},"MGCD516",{"EARLY_PHASE1":1340,"PHASE1":1342,"PHASE2":1353,"PHASE3":1355,"PHASE4":1357,"NA":1359},{"trials":1341,"activeCount":84},[],{"trials":1343,"activeCount":84},[1344],{"nctId":1345,"briefTitle":1346,"status":164,"phases":1347,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":1350,"conditions":1351,"interventions":1352},"NCT02219711","Phase 1\u002F1b Study of MGCD516 in Patients With Advanced Cancer",[72],"2022-04-27","2014-08",193,[15],[1338],{"trials":1354,"activeCount":84},[],{"trials":1356,"activeCount":84},[],{"trials":1358,"activeCount":84},[],{"trials":1360,"activeCount":84},[],{"intervention":688,"totalTrials":12,"cells":1362},{"EARLY_PHASE1":1363,"PHASE1":1365,"PHASE2":1371,"PHASE3":1373,"PHASE4":1375,"NA":1377},{"trials":1364,"activeCount":84},[],{"trials":1366,"activeCount":84},[1367],{"nctId":679,"briefTitle":680,"status":164,"phases":1368,"primaryCompletion":682,"completion":683,"start":684,"enrollment":685,"conditions":1369,"interventions":1370},[72],[17],[104,688,689],{"trials":1372,"activeCount":84},[],{"trials":1374,"activeCount":84},[],{"trials":1376,"activeCount":84},[],{"trials":1378,"activeCount":84},[],{"intervention":689,"totalTrials":12,"cells":1380},{"EARLY_PHASE1":1381,"PHASE1":1383,"PHASE2":1389,"PHASE3":1391,"PHASE4":1393,"NA":1395},{"trials":1382,"activeCount":84},[],{"trials":1384,"activeCount":84},[1385],{"nctId":679,"briefTitle":680,"status":164,"phases":1386,"primaryCompletion":682,"completion":683,"start":684,"enrollment":685,"conditions":1387,"interventions":1388},[72],[17],[104,688,689],{"trials":1390,"activeCount":84},[],{"trials":1392,"activeCount":84},[],{"trials":1394,"activeCount":84},[],{"trials":1396,"activeCount":84},[],{"intervention":260,"totalTrials":12,"cells":1398},{"EARLY_PHASE1":1399,"PHASE1":1401,"PHASE2":1407,"PHASE3":1409,"PHASE4":1411,"NA":1413},{"trials":1400,"activeCount":84},[],{"trials":1402,"activeCount":84},[1403],{"nctId":251,"briefTitle":252,"status":164,"phases":1404,"primaryCompletion":254,"completion":255,"start":256,"enrollment":257,"conditions":1405,"interventions":1406},[72],[15,20,25],[39,260],{"trials":1408,"activeCount":84},[],{"trials":1410,"activeCount":84},[],{"trials":1412,"activeCount":84},[],{"trials":1414,"activeCount":84},[],{"intervention":271,"totalTrials":12,"cells":1416},{"EARLY_PHASE1":1417,"PHASE1":1419,"PHASE2":1425,"PHASE3":1427,"PHASE4":1429,"NA":1431},{"trials":1418,"activeCount":84},[],{"trials":1420,"activeCount":84},[1421],{"nctId":262,"briefTitle":263,"status":92,"phases":1422,"primaryCompletion":265,"completion":266,"start":267,"enrollment":80,"conditions":1423,"interventions":1424},[72],[15,20,269,228,25],[39,271],{"trials":1426,"activeCount":84},[],{"trials":1428,"activeCount":84},[],{"trials":1430,"activeCount":84},[],{"trials":1432,"activeCount":84},[],{"intervention":1434,"totalTrials":12,"cells":1435},"Sitravatinib 50 mg",{"EARLY_PHASE1":1436,"PHASE1":1438,"PHASE2":1452,"PHASE3":1454,"PHASE4":1456,"NA":1458},{"trials":1437,"activeCount":84},[],{"trials":1439,"activeCount":84},[1440],{"nctId":1441,"briefTitle":1442,"status":164,"phases":1443,"primaryCompletion":1444,"completion":1445,"start":1446,"enrollment":639,"conditions":1447,"interventions":1448},"NCT05255276","PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.",[72],"2022-05-12","2023-02-10","2022-02-02",[17],[1434,1449,1450,1451],"Sitravatinib 100 mg","Itraconazole","Rifampin",{"trials":1453,"activeCount":84},[],{"trials":1455,"activeCount":84},[],{"trials":1457,"activeCount":84},[],{"trials":1459,"activeCount":84},[],{"intervention":1449,"totalTrials":12,"cells":1461},{"EARLY_PHASE1":1462,"PHASE1":1464,"PHASE2":1470,"PHASE3":1472,"PHASE4":1474,"NA":1476},{"trials":1463,"activeCount":84},[],{"trials":1465,"activeCount":84},[1466],{"nctId":1441,"briefTitle":1442,"status":164,"phases":1467,"primaryCompletion":1444,"completion":1445,"start":1446,"enrollment":639,"conditions":1468,"interventions":1469},[72],[17],[1434,1449,1450,1451],{"trials":1471,"activeCount":84},[],{"trials":1473,"activeCount":84},[],{"trials":1475,"activeCount":84},[],{"trials":1477,"activeCount":84},[],{"intervention":1450,"totalTrials":12,"cells":1479},{"EARLY_PHASE1":1480,"PHASE1":1482,"PHASE2":1488,"PHASE3":1490,"PHASE4":1492,"NA":1494},{"trials":1481,"activeCount":84},[],{"trials":1483,"activeCount":84},[1484],{"nctId":1441,"briefTitle":1442,"status":164,"phases":1485,"primaryCompletion":1444,"completion":1445,"start":1446,"enrollment":639,"conditions":1486,"interventions":1487},[72],[17],[1434,1449,1450,1451],{"trials":1489,"activeCount":84},[],{"trials":1491,"activeCount":84},[],{"trials":1493,"activeCount":84},[],{"trials":1495,"activeCount":84},[],{"intervention":1451,"totalTrials":12,"cells":1497},{"EARLY_PHASE1":1498,"PHASE1":1500,"PHASE2":1506,"PHASE3":1508,"PHASE4":1510,"NA":1512},{"trials":1499,"activeCount":84},[],{"trials":1501,"activeCount":84},[1502],{"nctId":1441,"briefTitle":1442,"status":164,"phases":1503,"primaryCompletion":1444,"completion":1445,"start":1446,"enrollment":639,"conditions":1504,"interventions":1505},[72],[17],[1434,1449,1450,1451],{"trials":1507,"activeCount":84},[],{"trials":1509,"activeCount":84},[],{"trials":1511,"activeCount":84},[],{"trials":1513,"activeCount":84},[],{"intervention":205,"totalTrials":12,"cells":1515},{"EARLY_PHASE1":1516,"PHASE1":1518,"PHASE2":1524,"PHASE3":1526,"PHASE4":1528,"NA":1530},{"trials":1517,"activeCount":84},[],{"trials":1519,"activeCount":84},[1520],{"nctId":196,"briefTitle":197,"status":164,"phases":1521,"primaryCompletion":199,"completion":200,"start":201,"enrollment":202,"conditions":1522,"interventions":1523},[72],[17],[53,205],{"trials":1525,"activeCount":84},[],{"trials":1527,"activeCount":84},[],{"trials":1529,"activeCount":84},[],{"trials":1531,"activeCount":84},[],{"intervention":216,"totalTrials":12,"cells":1533},{"EARLY_PHASE1":1534,"PHASE1":1536,"PHASE2":1542,"PHASE3":1544,"PHASE4":1546,"NA":1548},{"trials":1535,"activeCount":84},[],{"trials":1537,"activeCount":84},[1538],{"nctId":207,"briefTitle":208,"status":92,"phases":1539,"primaryCompletion":210,"completion":210,"start":211,"enrollment":9,"conditions":1540,"interventions":1541},[72],[213,214,15,20,25],[53,216],{"trials":1543,"activeCount":84},[],{"trials":1545,"activeCount":84},[],{"trials":1547,"activeCount":84},[],{"trials":1549,"activeCount":84},[],{"intervention":1551,"totalTrials":12,"cells":1552},"Treatment A",{"EARLY_PHASE1":1553,"PHASE1":1555,"PHASE2":1566,"PHASE3":1568,"PHASE4":1570,"NA":1572},{"trials":1554,"activeCount":84},[],{"trials":1556,"activeCount":84},[1557],{"nctId":1558,"briefTitle":1559,"status":164,"phases":1560,"primaryCompletion":1561,"completion":211,"start":1562,"enrollment":11,"conditions":1563,"interventions":1564},"NCT05868356","A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib",[72],"2023-07-25","2023-06-01",[17],[1551,1565],"Treatment B",{"trials":1567,"activeCount":84},[],{"trials":1569,"activeCount":84},[],{"trials":1571,"activeCount":84},[],{"trials":1573,"activeCount":84},[],{"intervention":1565,"totalTrials":12,"cells":1575},{"EARLY_PHASE1":1576,"PHASE1":1578,"PHASE2":1584,"PHASE3":1586,"PHASE4":1588,"NA":1590},{"trials":1577,"activeCount":84},[],{"trials":1579,"activeCount":84},[1580],{"nctId":1558,"briefTitle":1559,"status":164,"phases":1581,"primaryCompletion":1561,"completion":211,"start":1562,"enrollment":11,"conditions":1582,"interventions":1583},[72],[17],[1551,1565],{"trials":1585,"activeCount":84},[],{"trials":1587,"activeCount":84},[],{"trials":1589,"activeCount":84},[],{"trials":1591,"activeCount":84},[],{"intervention":1593,"totalTrials":12,"cells":1594},"MRTX1133",{"EARLY_PHASE1":1595,"PHASE1":1597,"PHASE2":1610,"PHASE3":1612,"PHASE4":1614,"NA":1616},{"trials":1596,"activeCount":84},[],{"trials":1598,"activeCount":84},[1599],{"nctId":1600,"briefTitle":1601,"status":92,"phases":1602,"primaryCompletion":1603,"completion":1603,"start":1604,"enrollment":1605,"conditions":1606,"interventions":1609},"NCT05737706","Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation",[72],"2025-03-10","2023-03-06",63,[291,22,1607,293,1608],"Non-small Cell Lung Cancer","Pancreatic Adenocarcinoma",[1593],{"trials":1611,"activeCount":84},[],{"trials":1613,"activeCount":84},[],{"trials":1615,"activeCount":84},[],{"trials":1617,"activeCount":84},[],{"intervention":282,"totalTrials":12,"cells":1619},{"EARLY_PHASE1":1620,"PHASE1":1622,"PHASE2":1628,"PHASE3":1630,"PHASE4":1632,"NA":1634},{"trials":1621,"activeCount":84},[],{"trials":1623,"activeCount":84},[1624],{"nctId":273,"briefTitle":274,"status":164,"phases":1625,"primaryCompletion":276,"completion":277,"start":278,"enrollment":279,"conditions":1626,"interventions":1627},[72],[22],[39,282],{"trials":1629,"activeCount":84},[],{"trials":1631,"activeCount":84},[],{"trials":1633,"activeCount":84},[],{"trials":1635,"activeCount":84},[],{"intervention":1637,"totalTrials":12,"cells":1638},"MGCD265+erlotinib",{"EARLY_PHASE1":1639,"PHASE1":1641,"PHASE2":1654,"PHASE3":1656,"PHASE4":1658,"NA":1660},{"trials":1640,"activeCount":84},[],{"trials":1642,"activeCount":84},[1643],{"nctId":1644,"briefTitle":1645,"status":92,"phases":1646,"primaryCompletion":1647,"completion":1349,"start":1648,"enrollment":1649,"conditions":1650,"interventions":1652},"NCT00975767","A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer",[72],"2013-07","2009-08",126,[1651],"Advanced Malignancies, Non-small Cell Lung Cancer",[1637,1653],"MGCD265+docetaxel",{"trials":1655,"activeCount":84},[],{"trials":1657,"activeCount":84},[],{"trials":1659,"activeCount":84},[],{"trials":1661,"activeCount":84},[],{"intervention":1653,"totalTrials":12,"cells":1663},{"EARLY_PHASE1":1664,"PHASE1":1666,"PHASE2":1672,"PHASE3":1674,"PHASE4":1676,"NA":1678},{"trials":1665,"activeCount":84},[],{"trials":1667,"activeCount":84},[1668],{"nctId":1644,"briefTitle":1645,"status":92,"phases":1669,"primaryCompletion":1647,"completion":1349,"start":1648,"enrollment":1649,"conditions":1670,"interventions":1671},[72],[1651],[1637,1653],{"trials":1673,"activeCount":84},[],{"trials":1675,"activeCount":84},[],{"trials":1677,"activeCount":84},[],{"trials":1679,"activeCount":84},[],{"intervention":295,"totalTrials":12,"cells":1681},{"EARLY_PHASE1":1682,"PHASE1":1684,"PHASE2":1690,"PHASE3":1692,"PHASE4":1694,"NA":1696},{"trials":1683,"activeCount":84},[],{"trials":1685,"activeCount":84},[1686],{"nctId":284,"briefTitle":285,"status":92,"phases":1687,"primaryCompletion":287,"completion":287,"start":288,"enrollment":289,"conditions":1688,"interventions":1689},[72],[291,22,292,293],[295,39],{"trials":1691,"activeCount":84},[],{"trials":1693,"activeCount":84},[],{"trials":1695,"activeCount":84},[],{"trials":1697,"activeCount":84},[]]